Bellevue Group AG Has $46.72 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bellevue Group AG trimmed its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 3.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 432,805 shares of the medical equipment provider's stock after selling 16,276 shares during the quarter. Bellevue Group AG owned approximately 0.22% of Zimmer Biomet worth $46,721,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Auxier Asset Management raised its holdings in shares of Zimmer Biomet by 3.4% in the third quarter. Auxier Asset Management now owns 63,573 shares of the medical equipment provider's stock valued at $6,863,000 after purchasing an additional 2,070 shares during the last quarter. Public Sector Pension Investment Board lifted its stake in Zimmer Biomet by 7.5% in the third quarter. Public Sector Pension Investment Board now owns 8,620 shares of the medical equipment provider's stock valued at $931,000 after purchasing an additional 600 shares during the last quarter. Providence Capital Advisors LLC lifted its position in shares of Zimmer Biomet by 8.6% during the 3rd quarter. Providence Capital Advisors LLC now owns 52,800 shares of the medical equipment provider's stock valued at $5,700,000 after buying an additional 4,191 shares during the last quarter. FORA Capital LLC lifted its holdings in Zimmer Biomet by 6.6% during the third quarter. FORA Capital LLC now owns 38,314 shares of the medical equipment provider's stock valued at $4,136,000 after purchasing an additional 2,371 shares during the last quarter. Finally, Glenmede Trust Co. NA increased its stake in shares of Zimmer Biomet by 163.9% in the third quarter. Glenmede Trust Co. NA now owns 44,554 shares of the medical equipment provider's stock worth $4,810,000 after purchasing an additional 27,673 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on ZBH shares. JPMorgan Chase & Co. reduced their price objective on shares of Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating for the company in a research note on Monday, September 16th. BTIG Research dropped their target price on Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating for the company in a research report on Thursday, October 3rd. Robert W. Baird reduced their price objective on Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Finally, Truist Financial raised their price target on Zimmer Biomet from $112.00 to $117.00 and gave the stock a "hold" rating in a research note on Friday, November 1st. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus price target of $123.22.

Zimmer Biomet Stock Up 0.1 %

ZBH traded up $0.08 during midday trading on Friday, hitting $112.10. 504,058 shares of the company's stock traded hands, compared to its average volume of 1,527,881. The company has a market cap of $22.32 billion, a PE ratio of 21.31, a price-to-earnings-growth ratio of 2.06 and a beta of 1.02. The stock's fifty day simple moving average is $107.29 and its 200-day simple moving average is $109.38. Zimmer Biomet Holdings, Inc. has a one year low of $101.47 and a one year high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion during the quarter, compared to analysts' expectations of $1.80 billion. During the same quarter in the prior year, the business earned $1.65 earnings per share. The company's revenue was up 4.1% on a year-over-year basis. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.